Skip to main content

Cercare Perfusion Implemented at Aarhus University Hospital for a Pilot Project

CERCARE Perfusion is implemented at Aarhus University Hospital (AUH), Denmark, to be used in a pilot project to assess treatment response in brain tumors.

Aarhus, Denmark (April 20) – CERCARE Perfusion is implemented at Aarhus University Hospital (AUH), Denmark, to be used in a pilot project to assess treatment response in brain tumors. AUH is one of the 5 national super hospitals in Denmark and is awarded Denmark’s Best Hospital 13 times in a row by the independent specialist newspaper of healthcare sector news ”Dagens Medicin”(1).

There are approximately 1,500 new cases of a primary brain tumor in Denmark each year, and about 15,000 people live with the diagnosis of primary brain tumor, including both patients in active treatment or follow-up regime or people in full recovery(2). After surgery, management of oncology patients for radiotherapy requires regular imaging follow-up to gauge the success of the treatment as well as the timely discovery of new tumor activity. Department of Radiology (Section of Neuroradiology) at AUH has decided to include perfusion imaging in follow-up which is technically difficult and requires a robust solution to ensure smooth clinical workflow.

The choice for a pilot project fell on CERCARE Perfusion provided by Cercare Medical, a spin-out from Aarhus University with a long history of collaboration in the field of acute stroke imaging and now extending their work to tumor imaging.

CERCARE Perfusion is a fully automated perfusion imaging solution with smart AIF selection powered by artificial intelligence. The technology is grounded in more than 15 years of research in perfusion imaging and is based on the unique approach that accounts for capillary function and integrity allowing to generate both traditional and unique parametric maps that reflect brain tissue oxygenation.

“We are very excited to have CERCARE Perfusion installed at AUH. This deepens our long-standing collaboration bringing innovation from early research to robust clinical usage. It was our goal to bring our research to life and make it available for healthcare professionals in clinical settings. We believe that our approach to perfusion imaging can have a significant influence on how patients are diagnosed and treated. As we continue broadening our installations across Europe and the USA, our continuous collaboration with AUH is very important to us and we look forward to having more projects together.”
Kim Beuschau Mouridsen, founder and CEO of Cercare Medical.

Would you like to receive updates with our news?